Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Scrap Unfair Company Criteria for Price Maintenance Premium: Japan Trade Group
The government should abolish new company criteria introduced in April for the so-called price maintenance premium (PMP), which narrow down the scope of drug makers that can receive a full price maintenance, because they lack fairness and predictability, Japan’s biggest…
To read the full story
Related Article
- Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
- Expand Exemption Criteria in New Off-Patent Price Cut Rule: Japan Pharma Lobby
June 19, 2018
- Japan Pharma Group Calls for Careful Approach on PMP Deduction for Comparator Drugs
June 19, 2018
- Don’t Make Coverage Decision on CEA, Tweak Prices with Limited Scope: FPMAJ
June 18, 2018
ORGANIZATION
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…